Drug delivery system for administration of AP 12009

DEVICE2 trials

Sponsors

Isarna Therapeutics GmbH

Conditions

Anaplastic AstrocytomaGlioblastoma

Phase 2

Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma

CompletedNCT00431561

Isarna Therapeutics GmbHAnaplastic Astrocytoma, Glioblastoma

Start: 2003-04-30End: 2009-03-31Updated: 2013-12-03

Phase 3

Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma

TerminatedNCT00761280

Isarna Therapeutics GmbHAnaplastic Astrocytoma, Glioblastoma

Start: 2008-12-31End: 2012-06-30Updated: 2014-11-14

Related Papers

New advances in cancer therapy targeting TGF-β signaling pathways

Molecular Therapy — Oncolytics2023-12-0127 citations

Mechanism of action (MOA) for TGF-ß2 driven survival.

JCO Global Oncology2023-08-01

Recurrent or Refractory High-Grade Gliomas Treated by Convection-Enhanced Delivery of a TGFβ2-Targeting RNA Therapeutic: A Post-Hoc Analysis with Long-Term Follow-Up

Cancers2019-11-2833 citations

ATIM-06. TREATMENT OF RECURRENT/REFRACTORY (R/R) ANAPLASTIC ASTROCYTOMA (AA, WHO GRADE 3) PATIENTS WITH ANTI-TGFß2 RNA THERAPEUTIC OT-101 VERSUS TEMOZOLOMIDE IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL

Neuro-Oncology2019-11-01

ATIM-10. CLINICAL PREDICTORS OF RESPONSE FOR RECURRENT/REFRACTORY GLIOBLASTOMA MULTIFORME (GBM) AND ANAPLASTIC ASTROCYTOMA (AA, WHO GRADE III) PATIENTS TREATED WITH THE ANTI-TGFß2 RNA THERAPEUTIC OT-101

Neuro-Oncology2019-11-01

ATIM-03. ANTI-TGFß2 RNA THERAPEUTIC OT-101 INDUCES DURABLE OBJECTIVE RESPONSES IN PATIENTS WITH RECURRENT/REFRACTORY (R/R) GLIOBLASTOMA MULTIFORME (GBM, WHO GRADE 4) OR ANAPLASTIC ASTROCYTOMA (AA, WHO GRADE 3)

Neuro-Oncology2019-11-01

Abstract 5029: OT-101/Chemotherapy- A novel mechanism of action (MOA) in glioblastoma immunization therapy

Cancer Research2019-07-01

Abstract 5029: OT-101/Chemotherapy- A novel mechanism of action (MOA) in glioblastoma immunization therapy

Clinical Research (Excluding Clinical Trials)2019-07-01

Proof of concept for the clinical utility of a convection enhanced delivery platform for immuno-oncology drugs against brain tumors

Cancer Reports and Reviews2019-01-012 citations